drugset
drugset / Trial / NCT02273388

BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours

NCT02273388 ↗

Phase 1 Completed 65 enrolled Boehringer Ingelheim
Non-randomizedSequentialOpen-labelTreatment

Summary

The primary objective of this trial is to identify the maximum tolerated dose (MTD) of BI 6727 therapy in terms of drug-related adverse events. Secondary objectives are the collection of overall safety and antitumour efficacy data and the determination of the pharmacokinetic profile of BI 6727.

Timeline

Start
2005-11-04
Primary completion
2009-01-19
Completion
2021-04-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Volasertib Small molecule 12 mg Intravenous
Subject Volasertib Small molecule 24 mg Intravenous
Subject Volasertib Small molecule 48 mg Intravenous
Subject Volasertib Small molecule 75 mg Intravenous
Subject Volasertib Small molecule 125 mg Intravenous
Subject Volasertib Small molecule 200 mg Intravenous
Subject Volasertib Small molecule 300 mg Intravenous
Subject Volasertib Small molecule 350 mg Intravenous
Subject Volasertib Small molecule 400 mg Intravenous
Subject Volasertib Small molecule 450 mg Intravenous

Indications

neoplasm